Business Context and Reporting Period
This Form 8-K is a current report filed by Imprimis Pharmaceuticals, Inc. (referred to in metadata as Harrow, Inc.) on October 15, 2015. The filing primarily announces the completion of an asset acquisition and references preliminary revenue results for the quarter ended September 30, 2015.
Key Financial Metrics
- Acquisition Cost: The Company paid a total cash purchase price of approximately $524,000 to acquire assets from Thousand Oaks Holding Company and its subsidiaries.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures. It references a press release (Exhibit 99.1) containing preliminary revenue results for the period ended September 30, 2015, but the numerical data is not included in this document.
- Cash Flow and Liquidity: No specific cash flow or liquidity metrics are disclosed in this text, other than the $524,000 cash outflow for the acquisition.
- Debt: The filing does not disclose specific debt levels or changes in debt obligations.
Material Changes
The primary material change reported is the closing of an Asset Purchase Agreement on October 15, 2015. ImprimisRx PA, Inc., a wholly-owned subsidiary, acquired substantially all assets of the Sellers, including intellectual property, trademarks, inventories, equipment, customer lists, and permits. The Company also assumed certain limited liabilities. Additionally, the Company issued revised revenue guidance for its 2015 year-end, though the specific revised figures are not detailed in this text.
Guidance, Outlook, and Risks
The Company has issued revised revenue guidance for the 2015 fiscal year, the details of which are contained in a separate press release (Exhibit 99.1). The filing includes a cautionary note regarding forward-looking statements, highlighting risks such as potential delays in transaction closing, difficulties in integration, and general regulatory developments impacting compounding pharmacies and the pharmaceutical industry. The Company explicitly states it has no obligation to update the forward-looking information provided.
Investor Verification Checklist
- Verify the specific preliminary revenue results and revised 2015 year-end guidance by reviewing the press release dated October 20, 2015 (Exhibit 99.1).
- Confirm the full terms of the Asset Purchase Agreement and the specific liabilities assumed by reviewing the document attached to the Form 10-Q for the quarter ended September 30, 2015.
- Assess the impact of the $524,000 cash outflow on the Company's current liquidity position.
- Monitor regulatory developments affecting compounding pharmacies and outsourcing facilities as identified in the risk factors.